[{"id":"ba972dc7-1762-477d-8b36-0d0d0ad7b71e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137900","created_at":"2021-01-27T18:59:11.341Z","updated_at":"2024-07-02T16:35:20.956Z","phase":"Phase 1","brief_title":"Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT04137900","lead_sponsor":"TopAlliance Biosciences","biomarkers":" BTLA","pipe":" | ","alterations":" PD-L1 expression","tags":["BTLA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tifcemalimab (TAB004)"],"overall_status":"Recruiting","enrollment":" Enrollment 499","initiation":"Initiation: 10/30/2019","start_date":" 10/30/2019","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-05"}]